{"id":7812,"date":"2026-02-24T06:08:29","date_gmt":"2026-02-24T06:08:29","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/glp-2-t\/"},"modified":"2026-04-09T14:26:23","modified_gmt":"2026-04-09T21:26:23","slug":"glp-1-t","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/glp-1-t\/","title":{"rendered":"GLP-1T \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to GLP-1T product page<\/a><\/p>\n

Ver reportes de laboratorio<\/a> \u00b7 Calidad y pruebas<\/a> \u00b7 Preguntas frecuentes<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on this compound \u2014 for educational purposes only<\/p>\n

\nMechanism as an imbalanced dual agonist<\/summary>\n
\n

GLP-1T is characterized as an “imbalanced” dual agonist because it displays full agonism at the GIP receptor but biased agonism at the GLP-1 receptor. At the GLP-1R, GLP-1T preferentially activates G\u03b1s-mediated cAMP signaling while exhibiting reduced \u03b2-arrestin recruitment compared to native GLP-1. This biased signaling profile results in less receptor internalization and potentially sustained receptor surface availability. The compound’s C-20 fatty diacid moiety enables albumin binding and alters its stability profile in preclinical characterization. Research compound \u2014 not for human use.<\/em><\/p>\n

Willard FS, et al. JCI Insight.<\/em> 2020;5(17):e140532. JCI Insight<\/a><\/p>\n<\/div>\n<\/details>\n

\nGLP-1R signaling vs selective GLP-1 agonists<\/summary>\n
\n

Unlike selective GLP-1 receptor agonists such as GLP-1 S, GLP-1T demonstrates biased agonism at GLP-1R characterized by reduced \u03b2-arrestin-1 recruitment. Selective GLP-1 agonists activate both cAMP and \u03b2-arrestin pathways with relatively balanced efficacy, leading to robust receptor internalization. GLP-1T’s biased profile \u2014 favoring cAMP over \u03b2-arrestin \u2014 may alter receptor trafficking dynamics. The simultaneous engagement of GIP receptors with full agonism distinguishes GLP-1T’s pharmacological signature from mono-agonist compounds. Research compound \u2014 not for human use.<\/em><\/p>\n

Min Q, et al. Proc Natl Acad Sci USA.<\/em> 2022;119(34):e2116506119. PNAS<\/a><\/p>\n<\/div>\n<\/details>\n

\ncAMP vs \u03b2-arrestin receptor pharmacology<\/summary>\n
\n

In cell-based assays, GLP-1T activates GIP receptor-mediated cAMP accumulation with potency comparable to native GIP. At the GLP-1 receptor, GLP-1T generates cAMP with approximately 5-fold lower potency than native GLP-1, but displays markedly reduced (>100-fold) \u03b2-arrestin-1 and \u03b2-arrestin-2 recruitment. This dissociation between G-protein signaling and arrestin recruitment defines GLP-1T as a G-protein-biased agonist at GLP-1R. Research compound \u2014 not for human use.<\/em><\/p>\n

Willard FS, et al. JCI Insight.<\/em> 2020;5(17):e140532. JCI Insight<\/a><\/p>\n<\/div>\n<\/details>\n

\nStructural basis for dual receptor engagement<\/summary>\n
\n

GLP-1T is a 39-amino acid linear peptide based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity. Key structural features include an \u03b1-aminoisobutyric acid (Aib) substitution at position 2 conferring DPP-4 resistance, and a C-20 fatty diacid moiety conjugated via a linker at lysine-20 enabling non-covalent albumin binding. The exendin-4-derived C-terminal extension (positions 35-39) contributes to GLP-1R engagement. Research compound \u2014 not for human use.<\/em><\/p>\n

Min Q, et al. Proc Natl Acad Sci USA.<\/em> 2022;119(34):e2116506119. PNAS<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to GLP-1T product page View Lab Reports \u00b7 Quality & Testing \u00b7 FAQ Research Library Published research on this compound \u2014 for educational purposes only Mechanism as an imbalanced dual agonist GLP-1T is characterized as an “imbalanced” dual agonist because it displays full agonism at the GIP receptor but biased agonism at the […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7812","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7812"}],"version-history":[{"count":5,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7812\/revisions"}],"predecessor-version":[{"id":8643,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7812\/revisions\/8643"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}